公开(公告)号：US06552083B1

公开(公告)日：2003-04-22

申请号：US10030915

申请日：2002-05-23

申请人： Mitsuaki Isobe ,  Atsushi Izawa

发明人： Mitsuaki Isobe ,  Atsushi Izawa

IPC分类号： A61K3124

CPC分类号： A61K31/196 ,  Y10S514/824 ,  Y10S514/885

摘要： The present invention relates to an agent for inhibiting diseases associated with chronic rejection after organ transplantation, such as transplanted heart-accelerated coronary arteriosclerosis, containing as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by formula: or a pharmaceutically acceptable salt thereof, which has an inhibitory effect on vascular thickening in transplanted hearts.

摘要翻译： 本发明涉及用于抑制器官移植后与慢性排斥有关的疾病的药剂，例如含有作为活性成分的移植的心脏加速冠状动脉硬化，其包含式（I）表示的N-（3,4-二甲氧基肉桂酰基）邻氨基苯甲酸或其药学上可接受的盐 其可接受的盐对移植的心脏中的血管增厚具有抑制作用。

公开(公告)号：US09562103B2

公开(公告)日：2017-02-07

申请号：US12524041

申请日：2008-01-23

申请人： Masafumi Takahashi ,  Atsushi Izawa

发明人： Masafumi Takahashi ,  Atsushi Izawa

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

摘要： The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

公开(公告)号：US20090263384A1

公开(公告)日：2009-10-22

申请号：US12085065

申请日：2006-11-15

申请人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

发明人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

IPC分类号： A61K39/395 ,  A61P37/06

CPC分类号： C07K16/248 ,  A61K2039/505 ,  C07K16/2866

摘要： The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

摘要翻译： 检测抗IL-6受体抗体在抑制细胞毒T细胞诱导中的作用。 结果表明，与未用抗体治疗的小鼠相比，用对照抗体处理的小鼠相比，用抗IL-6受体抗体处理的小鼠中，抗同种异体抗体的CTL活性显着降低。 还将抗IL-6受体抗体施用于用于同种异体心脏移植的小鼠模型的受体。 结果，组织病理学检查结果显示，移植心脏的炎症细胞浸润被抑制，移植心脏的存活期显着延长。 因此，本发明人首次发现，抗IL-6受体抗体的施用可以抑制细胞毒性T细胞诱导，从而抑制移植后的急性排斥反应。

公开(公告)号：US20090032984A1

公开(公告)日：2009-02-05

申请号：US12170209

申请日：2008-07-09

申请人： Masayuki Iwase ,  Atsushi Izawa ,  Yozo Ishikawa

发明人： Masayuki Iwase ,  Atsushi Izawa ,  Yozo Ishikawa

IPC分类号： G02B6/04

CPC分类号： G02B6/1228 ,  G02B6/2558 ,  G02B6/3636 ,  G02B6/3885 ,  G02B6/4214 ,  G02B6/4246

摘要： A method for manufacturing optical fibers with filter, wherein a multilayer-film filter is formed at end face of the optical fibers, comprising a process for fixing each of the optical fibers on a fixing jig, a process for polishing the end face of the optical fiber fixed on said fixing jig, a process for film-forming a filter on the end face of the optical fibers after polishing, and a process for taking out said optical fibers from said fixing jigs, respectively, wherein said process for film-forming the filter is performed by forming a fiber bundle in which a plural number of optical fibers after polishing, on which the filter has been film-formed, are tied such that all polished planes are aligned at the end face.

摘要翻译： 一种用于制造具有滤光器的光纤的方法，其中在光纤的端面处形成多层膜滤光器，包括用于将每个光纤固定在定影夹具上的工艺，用于抛光光学端面的工艺 固定在所述固定夹具上的纤维，在抛光之后在光纤的端面上形成滤光器的方法，以及分别从所述固定夹具取出所述光纤的工艺，其中所述成膜方法 通过形成纤维束进行滤光器，其中在其上已经形成有滤光器的抛光之后的多个光纤被束缚，使得所有抛光平面在端面对齐。

公开(公告)号：US07412148B2

公开(公告)日：2008-08-12

申请号：US10531709

申请日：2003-10-17

申请人： Masayuki Iwase ,  Atsushi Izawa ,  Yozo Ishikawa

发明人： Masayuki Iwase ,  Atsushi Izawa ,  Yozo Ishikawa

IPC分类号： G02B6/00 ,  G02B6/36

CPC分类号： G02B6/364 ,  G02B6/1228 ,  G02B6/2558 ,  G02B6/3652 ,  G02B6/3885 ,  G02B6/4214 ,  G02B6/4246

摘要： An optical component provided with a waveguide groove having, an waveguide holding plane having a surface shape extending along a specified axial direction and capable of holding at least one optical waveguide while positioning it at at least a part of at least one side face thereof; and an opening extending substantially oppositely to the waveguide holding plane and being smaller in width than the outside diameter of at least one optical waveguide in a specified widthwise direction perpendicular to the specified axial direction.

摘要翻译： 一种具有波导槽的光学部件，具有波导保持平面，所述波导保持平面具有沿着规定的轴向延伸的表面形状，并且能够保持至少一个光波导，同时将其定位在其至少一个侧面的至少一部分; 以及与所述波导保持面大致相反地延伸的开口，并且在垂直于所述规定的轴向的规定的宽度方向上的宽度小于至少一个光波导的外径。

公开(公告)号：US06608725B2

公开(公告)日：2003-08-19

申请号：US09893320

申请日：2001-06-26

申请人： Atsushi Izawa ,  Masayuki Iwase

发明人： Atsushi Izawa ,  Masayuki Iwase

IPC分类号： G02B702

CPC分类号： G02B6/4201 ,  G02B6/4239 ,  H01L25/167 ,  H01L31/0203 ,  H01L2224/48091 ,  H01L2224/48137 ,  H01L2224/8592 ,  H01L2924/00014 ,  H01L2924/09701 ,  H01L2224/45099

摘要： An optical module, in which an optical device can be mounted and repaired without damaging an electrode on an electronic device side, is provided. A photodiode (1) and a pre-amplifier IC (2) are mounted on a base (stem) (4), and except for that, a relay terminal table (7) is provided. The photodiode (1) and the pre-amplifier IC (2) are connected through the relay terminal table (7) by means of bonding wires (3a, 3b). The relay terminal table (7) is connected via the bonding wire (3a) to an electrode (11) of the photodiode (1), as well as via the bonding wire (3b) to an electrode (12) of the pre-amplifier IC (2). In repairing the photodiode (1) only the bonding wire (3a) is removed for re-wiring, so that the electrode (12) of the pre-amplifier IC can be prevented from being damaged.

公开(公告)号：US09725514B2

公开(公告)日：2017-08-08

申请号：US12524041

申请日：2008-01-23

申请人： Masafumi Takahashi ,  Atsushi Izawa

发明人： Masafumi Takahashi ,  Atsushi Izawa

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/76

摘要： The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

公开(公告)号：US08623355B2

公开(公告)日：2014-01-07

申请号：US12085065

申请日：2006-11-15

申请人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

发明人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  A61P37/06

CPC分类号： C07K16/248 ,  A61K2039/505 ,  C07K16/2866

摘要： The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

摘要翻译： 检测抗IL-6受体抗体在抑制细胞毒T细胞诱导中的作用。 结果表明，与未用抗体治疗的小鼠相比，用对照抗体处理的小鼠相比，用抗IL-6受体抗体处理的小鼠中，抗同种异体抗体的CTL活性显着降低。 还将抗IL-6受体抗体施用于用于同种异体心脏移植的小鼠模型的受体。 结果，组织病理学检查结果显示，移植心脏的炎症细胞浸润被抑制，移植心脏的存活期显着延长。 因此，本发明人首次发现，抗IL-6受体抗体的施用可以抑制细胞毒性T细胞诱导，从而抑制移植后的急性排斥反应。

公开(公告)号：US20100061986A1

公开(公告)日：2010-03-11

申请号：US12524041

申请日：2008-01-23

申请人： Masafumi Takahashi ,  Atsushi Izawa

发明人： Masafumi Takahashi ,  Atsushi Izawa

IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P37/06

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/76

摘要： The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

摘要翻译： 本发明人评估了抗IL-6受体抗体在抑制慢性排斥反应中的作用。 他们使用小鼠模型评估了抗小鼠IL-6受体抗体（MR16-1）给药抑制慢性排斥反应对心脏移植后慢性排斥反应的影响。 移植后60天移植的心脏组织病理学分析结果显示，MR16-1治疗组与对照组相比，心肌和血管狭窄病变纤维化（其为慢性排斥反应特征的病理状态）明显抑制 组。 因此，MR16-1给药被证明具有抑制慢性排斥反应的作用。 具体地，本发明人首次发现通过施用抗IL-6受体抗体抑制器官移植后的慢性期的排斥反应。